OncoMatch/Clinical Trials/NCT06171607
Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses
Is NCT06171607 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Perflutren Lipid Microspheres and Sulfur Hexafluoride Lipid Microspheres for breast carcinoma.
Treatment: Perflutren Lipid Microspheres · Sulfur Hexafluoride Lipid Microspheres — This clinical trial investigates the role of contrast enhanced ultrasound (CEUS) in identifying cystic breast masses as benign or malignant. Ultrasound is a diagnostic imaging test that uses sound waves to make pictures of the body without using radiation (x-rays). Ultrasounds are widely used to diagnose many diseases in the body. This trial may help researchers learn if using CEUS will help in determining whether or not an ultrasound guided biopsy is necessary.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Prior therapy
Cannot have received: neoadjuvant chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Los Angeles County-USC Medical Center · Los Angeles, California
- USC / Norris Comprehensive Cancer Center · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify